Psoriatic arthritis is an autoimmune disease. The immune system mistakenly attacks healthy tissue in the joints, tendons, and skin, causing chronic inflammation and, if untreated, permanent joint damage. Up to 30% of people with psoriasis eventually develop psoriatic arthritis, with an overall prevalence of about 12% among psoriasis patients.
Why It’s Classified as Autoimmune
The hallmark of an autoimmune disease is the body’s immune system targeting its own tissues. In psoriatic arthritis, specific immune cells called CD8 T cells become “auto-reactive,” meaning they attack proteins found naturally in joint and tendon tissue. Gene expression studies show that two immune pathways overactive in psoriatic arthritis, type I interferon signaling and a pathway driven by a cell type called Th17, are a signature combination seen across autoimmune diseases like lupus, type 1 diabetes, and inflammatory bowel disease.
The attack isn’t random. Certain genetic markers on immune cells (called HLA class I molecules) appear to bind to the body’s own proteins from joint and tendon tissue, then present those proteins to immune cells as if they were foreign invaders. This triggers a misdirected immune response that sustains chronic inflammation.
Under a microscope, the inflamed joint lining in psoriatic arthritis shows an overgrowth of its surface layer along with dense clusters of immune cells: T cells, B cells, macrophages, and plasma cells. Those plasma cells produce a signaling molecule that triggers joint-lining cells to churn out inflammatory chemicals, creating a self-reinforcing cycle of tissue damage.
The Immune Signals Driving Joint and Skin Damage
Three key inflammatory signals do most of the damage in psoriatic arthritis. TNF-alpha is found at high levels at sites of inflammation and fuels the accumulation of activated immune cells in joints. Its importance is underscored by the dramatic improvement many patients experience when treated with drugs that block it.
IL-17, produced by several types of immune cells, drives inflammation along multiple fronts. It recruits waves of neutrophils and macrophages into joint tissue, stimulates blood vessel growth that feeds inflamed areas, and causes skin cells to multiply abnormally. This is why the same immune signal contributes to both swollen joints and psoriasis plaques.
IL-23 acts as an amplifier. It promotes the survival and expansion of the Th17 cells that produce IL-17, creating a feedback loop. It also directly promotes bone erosion by encouraging the formation of osteoclasts, the cells that break down bone. In the skin, IL-23 works alongside IL-17 to trigger the rapid skin cell turnover that produces scaly plaques.
Who Develops It and Why
Genetics play a significant role. The gene HLA-B27, well known for its link to ankylosing spondylitis, also raises the risk of psoriatic arthritis. In one study, about one-third of patients with psoriatic arthritis affecting the small joints of the fingers were HLA-B27 positive, a rate far higher than in the general population. Every patient in that study who had psoriasis with ankylosing spondylitis (spinal inflammation) was HLA-B27 positive. Other genetic markers, including HLA-B38, HLA-B39, and HLA-DR4, may also contribute risk, though the evidence is less definitive.
Having psoriasis is the strongest single risk factor. The condition can appear at any age, but most people develop it between ages 30 and 50. In some cases, joint symptoms appear before skin symptoms or without obvious skin involvement at all, which can make diagnosis tricky.
How It Feels and What to Look For
Psoriatic arthritis affects joints, tendons, and sometimes the spine. The pattern varies widely from person to person, but a few features set it apart from other forms of arthritis.
Dactylitis, commonly called “sausage digits,” is swelling of an entire finger or toe rather than just one joint. It’s considered a marker of more severe disease because it tends to be associated with permanent joint damage if left untreated. Enthesitis is pain and inflammation where tendons or ligaments attach to bone, commonly at the Achilles tendon, the bottom of the foot, or around the elbow. This type of pain doesn’t occur in rheumatoid arthritis, making it a useful distinguishing feature.
Nail changes are another clue. Pitting (small dents in the nail surface), ridging, crumbling, or separation of the nail from the nail bed occur frequently and sometimes appear years before joint symptoms.
How It Differs From Rheumatoid Arthritis
The two conditions can look similar, especially when psoriatic arthritis affects small joints symmetrically. The key difference is in blood tests. Rheumatoid arthritis typically produces positive results for rheumatoid factor and anti-CCP antibodies. Psoriatic arthritis is generally “seronegative,” meaning these markers are negative. However, the distinction isn’t absolute. Some psoriatic arthritis patients do test positive for anti-CCP antibodies at higher rates than people with skin psoriasis alone, which can occasionally complicate diagnosis.
Doctors use the CASPAR criteria to classify psoriatic arthritis. You need evidence of inflammatory joint, spine, or tendon disease plus at least 3 points from a checklist: current psoriasis scores 2 points, while a personal or family history of psoriasis, nail changes, a negative rheumatoid factor test, dactylitis, or X-ray evidence of new bone formation near joints each score 1 point.
Cardiovascular and Metabolic Risks
Because psoriatic arthritis involves system-wide inflammation, it doesn’t stay confined to the joints. People with the condition face a higher risk of cardiovascular disease compared to the general population, and that risk exceeds even that of people with skin psoriasis alone. Studies using ultrasound have found a greater burden of artery plaques in psoriatic arthritis patients, and having plaques on both sides of the neck nearly triples the risk of a cardiovascular event.
Metabolic changes run deeper than standard cholesterol panels reveal. Researchers using advanced blood analysis found abnormal levels of 19 different metabolic markers in psoriatic patients compared to healthy controls, spanning lipoprotein subclasses, fatty acids, amino acids, and blood sugar intermediates. These findings help explain why psoriatic arthritis is linked to higher rates of metabolic syndrome, even after accounting for traditional risk factors like weight and blood pressure.
How It’s Treated
Current guidelines from the American College of Rheumatology and the National Psoriasis Foundation recommend a “treat-to-target” approach, meaning therapy is adjusted until a specific goal, usually low disease activity or remission, is reached. For people starting treatment for active psoriatic arthritis, biologic drugs that block TNF-alpha are recommended as a first-line option over oral medications.
If TNF blockers don’t work well enough or aren’t tolerated, other biologics targeting IL-17 or IL-23 are effective alternatives, which makes sense given the central role these signals play in driving the disease. The choice often depends on whether joint symptoms or skin symptoms are more prominent, since different biologics vary in how well they address each.
Early treatment matters. Joint damage from psoriatic arthritis is irreversible once it occurs, and features like dactylitis signal that damage may be progressing. The goal is to suppress the autoimmune process before it causes structural changes visible on imaging.